Safety and efficacy of tick-borne encephalitis vaccine
- Conditions
- Tick-borne encephalitis
- Registration Number
- JPRN-UMIN000035862
- Lead Sponsor
- Sapporo City General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Not provided
1. Patients suspected with acute illness such as fever 2. Patients currently under treatment for any acute illness or patients who have not recovered from acute illness for more than 1 week 3. Severe immunodeficiency 4. History of severe adverse reaction or allergy after tick-borne encephalitis vaccine 5. Hypersensitivity to formaldehyde, neomycin, gentamycin, protamine sulfate) 6. Severe hypersensitivity to egg and chick proteins (anaphylactic reaction after oral ingestion of egg protein) 7. Severe hypersensitivity to latex (anaphylactic reaction to latex) 8. Pregnancy or breastfeeding 9. Participants who deemed inappropriate by principal investigator 10. For first time vaccination: tick bite within 4 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method